Royalty Pharma plc (RPRX)

Royalty Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	1,324	1,331	1,700	-	-
Depreciation & Amortization	3.85	-	-	-	-
Stock-Based Compensation	289.89	2.34	2.36	-	-
Other Adjustments	-2,466	-1,601	-1,921	-	-
Changes in Accounts Payable	-13.93	-2.29	6.24	-	-
Changes in Accrued Expenses	8.93	46.38	-2.48	-	-
Changes in Other Operating Activities	2,478	2,778	2,989	2,144	2,018
Operating Cash Flow	2,490	2,769	2,988	2,144	2,018
Operating Cash Flow Growth	-10.08%	-7.32%	39.36%	6.27%	-0.84%
Purchases of Investments	-2,202	-2,822	-2,140	-2,575	-3,647
Proceeds from Sale of Investments	566.5	118.36	25.83	1,546	1,776
Payments for Business Acquisitions	-74.42	-	-	-	-
Other Investing Activities	96.2	25.68	41.84	-	0.52
Investing Cash Flow	-1,614	-2,678	-2,073	-1,029	-1,870
Short-Term Debt Issued	1,275	-	350	-	-
Short-Term Debt Repaid	-1,275	-	-350	-	-
Long-Term Debt Issued	1,954	1,471	-	-	1,273
Long-Term Debt Repaid	-1,000	-	-1,000	-	-
Net Long-Term Debt Issued (Repaid)	954.48	1,471	-1,000	-	1,273
Repurchase of Common Stock	-1,227	-229.65	-304.76	-	-
Net Common Stock Issued (Repurchased)	-1,227	-229.65	-304.76	-	-
Common Dividends Paid	-378.25	-376.47	-358.33	-333.32	-285.18
Other Financing Activities	-534.81	-503.97	-485.67	-611.53	-602.24
Financing Cash Flow	-1,186	361.15	-2,149	-944.86	385.11
Net Cash Flow	-310.33	452.02	-1,234	169.7	532.37
Free Cash Flow	2,490	2,769	2,988	2,144	2,018
Free Cash Flow Growth	-10.08%	-7.32%	39.36%	6.27%	-0.84%
FCF Margin	104.69%	122.33%	126.89%	95.83%	88.12%
Free Cash Flow Per Share	4.41	4.66	4.96	4.90	4.86
Levered Free Cash Flow	4,202	5,153	3,128	2,187	3,910
Unlevered Free Cash Flow	4,036	4,115	4,485	2,451	3,448

Updated Feb 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q